We expect HCG to deliver a healthy Ebitda CAGR of 19% over FY2018-20 and valuations are now reasonable at 13X FY2020e Ebitda. Upgrade to BUY with a target price of Rs 270 (versus Rs 290 earlier).
Pregnancy testing has become more convenient and reliable with the introduction of the CLINITEST® hCG test for use with the CLINITEK Status® family of analyzers. The CLINITEST hCG pregnancy test ...
Private equity giant KKR has signed a definitive agreement to pick up a controlling stake in cancer care hospital chain Healthcare Global Enterprises (HCG) from CVC Asia V for $400 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results